Stephen Knight is president of Fidelity Biosciences, a unit of Fidelity Investments, overseeing Fidelity's private equity investing in biotechnology interests.
Dr. Knight has worked in the pharmaceutical and biotechnology industries for over fifteen years. Prior to joining Fidelity in 2003, Dr. Knight was president and chief operating officer for EPIX Medical, Inc. in Cambridge, MA. For the six years before joining EPIX, Dr. Knight worked at Arthur D. Little Inc. primarily as a senior consultant in Cambridge and Brussels, Belgium specializing in mergers and acquisitions in the pharmaceutical industry. Prior to 1990, Dr. Knight performed research at AT&T Bell Laboratories (now Lucent Technologies), the National Institute of Neurological and Communicative Diseases and Stroke, and at Yale University.
Dr. Knight holds an M.D. from the Yale University School of Medicine and an M.B.A. from the Yale School of Organization and Management. Dr. Knight received a bachelor of science degree in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.
Dr. Knight currently serves as chairman of the Board of Directors for Veritas Medicine and EnVivo Pharmaceuticals. He also serves on the Board of Directors of U.S. Genomics and Microbia. Previously he was a director at Pharmos, Inc. (NASDAQ:PARS).